• SII plans to launch Covovax by June: Poonawalla
    Pune, January 30 (IANS): In what could be a mega boost to the ongoing Covid-19 vaccination drive in India, the Serum Institute of India (SII) has announced its plan to launch its new vaccine, Covovax, by June this year. SII CEO Adar Poonawalla said on Saturday that its partnership for a Covid-19 vaccine with Novavax has shown excellent efficacy results. "We have applied for starting trials in India. Hope to launch Covocax by June 2021," Poonawalla said in a tweet. Th
  • SII expects nod for Covid-19 vaccine in 'few days'
    New Delhi, December 28 (IANS): Pune-based Serum Institute of India on Monday expressed hope at the possibility of Covid-19 vaccine - Covishield receiving the regulatory approval in "few days", while emphasising that the company has a massive stockpile 40-50 million doses. The drug maker has partnered with global pharma giant AstraZeneca and the Oxford University for making the vaccine and is conducting trials in India. Indian drug regulatory body is looking at the UK's
  • Centre seeks 300-400 mn vaccine doses, says SII's Poonawalla
    Pune, November 28 (IANS): The Government of India is looking at getting 300-400 million doses of coronavirus vaccine by July, which is being developed by an international health consortium that includes Punes Serum Institute of India (SII), a top official said here on Saturday. The Covidshield vaccine is being developed jointly by the Oxford University, AstraZeneca and SII. SII is the world's largest vaccine manufacturer, where Prime Minister Narendra Modi spent time on Saturday
  • Serum Institute to manufacture 200mn doses of Covid-19 vaccine
    New Delhi, September 29 (IANS) A further collaboration among the Serum Institute of India (SII), the world's largest vaccine manufacturer by volume, Gavi and the Bill and Melinda Gates Foundation will accelerate the manufacture and delivery of up to 100 million doses of safe and effective Covid-19 vaccines for India and low-and middle income countries. This brings the total number of vaccine doses to be covered by the partnership between SII, Gavi, and the Gates Foundation